(Total Views: 444)
Posted On: 04/03/2021 11:42:13 PM
Post# of 81
Journal of Psychedelic Studies 3-2021
Volume/Issue: Accepted Manuscript / Online First
A narrative review of the pharmacological, cultural and psychological literature on ibogaine
https://akjournals.com/view/journals/2054/aop...52.xml#B49
MindMed mentioned (in reference to PR)
A synthetic analogue of ibogaine was developed in 1996, 18-methoxycoronaridine (18-MC). The aim of 18-MC was to create a non-psychoactive medicine that retained ibogaine’s reported ability to effectively eliminate opioid withdrawal. In 2013, Savant HWP received a grant of $6.5 million from the USA National Institute on Drug Abuse (NIDA) for preclinical development of 18-MC. At the time of writing, a Phase 1 human clinical trial of 18-MC had been completed and planning for Phase 2a clinical research was allegedly underway (MindMed completes dosing, 2020).
MindMed completes dosing 18-MC phase 1 study. (2020, July 28). Retrieved on 2 January 2021 from https://mindmed.co/news/press-release/mindmed...e-1-study/.
Volume/Issue: Accepted Manuscript / Online First
A narrative review of the pharmacological, cultural and psychological literature on ibogaine
https://akjournals.com/view/journals/2054/aop...52.xml#B49
MindMed mentioned (in reference to PR)
A synthetic analogue of ibogaine was developed in 1996, 18-methoxycoronaridine (18-MC). The aim of 18-MC was to create a non-psychoactive medicine that retained ibogaine’s reported ability to effectively eliminate opioid withdrawal. In 2013, Savant HWP received a grant of $6.5 million from the USA National Institute on Drug Abuse (NIDA) for preclinical development of 18-MC. At the time of writing, a Phase 1 human clinical trial of 18-MC had been completed and planning for Phase 2a clinical research was allegedly underway (MindMed completes dosing, 2020).
MindMed completes dosing 18-MC phase 1 study. (2020, July 28). Retrieved on 2 January 2021 from https://mindmed.co/news/press-release/mindmed...e-1-study/.
(0)
(0)
